1h Free Analyst Time
The pulmonary embolism therapeutics market is forecasted to grow by USD 14.02 billion during 2023-2028, accelerating at a CAGR of 10.93% during the forecast period. The report on the pulmonary embolism therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing risk of adverse health conditions, increase in geriatric population, and rise in research and development activities for pulmonary embolism therapeutics.
The pulmonary embolism therapeutics market is segmented as below:
By Application
- Hospitals
- Ambulatory surgical centers
- Research institutes
By Route Of Administration
- Oral
- Parenteral
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the pulmonary embolism therapeutics market covers the following areas:
- Pulmonary embolism therapeutics market sizing
- Pulmonary embolism therapeutics market forecast
- Pulmonary embolism therapeutics market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by Route of Administration
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global pulmonary embolism therapeutics market: AbbVie Inc., Amgen Inc., Anthos Therapeutics, argenx SE, Astellas Pharma Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Inari Medical Inc., Johnson and Johnson Services Inc., Medtronic Plc, Novartis AG, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and Viatris Inc..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is advancements in healthcare and medical sector."
According to the report, one of the major drivers for this market is the growing risk of adverse health conditions.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Amgen Inc.
- Anthos Therapeutics
- argenx SE
- Astellas Pharma Inc.
- Bayer AG
- Boehringer Ingelheim International GmbH
- Bristol Myers Squibb Co.
- Daiichi Sankyo Co. Ltd.
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- Gilead Sciences Inc.
- Inari Medical Inc.
- Johnson and Johnson Services Inc.
- Medtronic Plc
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Takeda Pharmaceutical Co. Ltd.
- Viatris Inc.
